We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Novel Mechanical Device Removes 100% of Blood Clot in Ischemic Stroke Patients

By HospiMedica International staff writers
Posted on 25 Feb 2023

The mechanical solutions currently available for removing clots in ischemic stroke patients are based on stents that open inside the clot without aspiration, resulting in fragmentation of the clot. More...

This can create new blockages downstream and cause secondary damage to the brain tissue. A marginal reduction in blood flow during the clot removal procedure can significantly impact the patient's future quality of life. Now, a new approach to clot-retrieving procedures and stroke treatment minimizes the risk of clot fragmentation during mechanical thrombectomy, thereby reducing complications and improving outcomes.

Therma Bright Inc. (Toronto, Canada), in partnership with Inretio Inc. (Nir Am, Israel), is developing the PREVA device for mechanically removing blood clots in the brain, which is a critical factor in the treatment of ischemic stroke. PREVA is the first and only protective clot retriever that uses a unique distal basket which "ensnares" the clot, encapsulating it and protecting the brain from any sub-clots breaking off during the thrombectomy procedure. This ensures complete removal of the clot and its fragments, resulting in more successful revascularization of the brain which can prevent additional damage and complications as well as enhance patient outcomes. In a new study, the PREVA device demonstrated the ability to remove 100% of a blood clot in 85% of the cases, marking a significant step forward for the device's future development and potential regulatory approval and commercialization.

"We are thrilled with the progress of our PREVA device and the positive results we've seen in the GLP study," said Raviv Vine, CEO of Inretio. "Our team has worked tirelessly to develop a device that could make a meaningful difference in the treatment of ischemic stroke, and we believe that these results bring us one step closer to achieving that goal."

"We are very pleased about the progress of the GLP study and share Inretio's excitement around the potential this life saving ischemic stroke treatment technology can bring to the marketplace," shared Rob Fia, CEO of Therma Bright. "According to the CDC, every 40 seconds in the U.S. alone someone suffers from a stroke, and every 3.5 minutes someone dies. This is a serious medical issue and one that Inretio, in partnership with Therma Bright, looks to address with the PREVA device."

Related Links:
Therma Bright Inc.
Inretio Inc.


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Radiation Safety Barrier
RayShield Intensi-Barrier
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.